Wealthspire Advisors (Maryland)’s Armata Pharmaceuticals ARMP Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio ARMP Stock Details ARMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-71	Closed	–	–	560
2019 Q1	$0	Hold	71	–	–	﹤0.01%	2471
2018 Q4	$0	Hold	71	–	–	﹤0.01%	2424
2018 Q3	$1K	Hold	71	–	–	﹤0.01%	2250
2018 Q2	$1K	Hold	71	–	–	﹤0.01%	2273
2018 Q1	$1K	Buy	+71	New	+$1.26K	﹤0.01%	2292

Other funds holding ARMP

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s ARMP Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Armata Pharmaceuticals (ARMP) in Q2 2019, closing a stake of 71 shares.

Wealthspire Advisors (Maryland) first reported a position in ARMP in Q1 2018 and held it in 5 quarters. The position peaked at $1K in Q3 2018. 12 funds tracked by Wall St. Rank hold ARMP as of Q2 2019.

Wealthspire Advisors (Maryland) reported no remaining Armata Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Wealthspire Advisors (Maryland) sold 71 Armata Pharmaceuticals shares in Q2 2019.
Wealthspire Advisors (Maryland) first reported a position in Armata Pharmaceuticals in Q1 2018 and held it in 5 quarters.
Wealthspire Advisors (Maryland)'s Armata Pharmaceuticals position peaked at $1K in Q3 2018.
12 funds tracked by Wall St. Rank held Armata Pharmaceuticals as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.